Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 151

1.

Anaphylaxis-like reaction to anti-BRAF inhibitor dabrafenib confirmed by drug provocation test.

Seremet T, Haccuria A, Lienard D, Del Marmol V, Neyns B.

Melanoma Res. 2019 Feb;29(1):95-98. doi: 10.1097/CMR.0000000000000529.

PMID:
30383722
2.

Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma.

Seremet T, Planken S, Schwarze JK, Jansen Y, Vandeweerd L, van den Begin R, Tsechelidis I, Lienard D, Del Marmol V, Neyns B.

Melanoma Res. 2019 Feb;29(1):85-88. doi: 10.1097/CMR.0000000000000501.

PMID:
30211812
3.

Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy.

Seremet T, Planken S, Schreuer M, Jansen Y, Delaunoy M, El Housni H, Lienard D, Del Marmol V, Heimann P, Neyns B.

Melanoma Res. 2018 Feb;28(1):65-70. doi: 10.1097/CMR.0000000000000415.

PMID:
29227333
4.

Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients.

Seremet T, Koch A, Jansen Y, Schreuer M, Wilgenhof S, Del Marmol V, Liènard D, Thielemans K, Schats K, Kockx M, Van Criekinge W, Coulie PG, De Meyer T, van Baren N, Neyns B.

J Transl Med. 2016 Aug 2;14(1):232. doi: 10.1186/s12967-016-0990-x.

5.

Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.

Seremet T, Lienard D, Suppa M, Trepant AL, Rorive S, Woff E, Cuylits N, Jansen Y, Schreuer M, Del Marmol V, Neyns B.

Melanoma Res. 2015 Apr;25(2):180-3. doi: 10.1097/CMR.0000000000000145.

PMID:
25643238
6.

Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure.

Schreuer MS, Chevolet IL, Jansen YJ, Seremet TC, Wilgenhof S, Liénard D, Del Marmol V, Neyns B.

Melanoma Res. 2015 Feb;25(1):68-74. doi: 10.1097/CMR.0000000000000131.

PMID:
25396684
7.

Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma.

Wilgenhof S, Du Four S, Vandenbroucke F, Everaert H, Salmon I, Liénard D, Marmol VD, Neyns B.

J Immunother. 2013 Apr;36(3):215-22. doi: 10.1097/CJI.0b013e31828eed39.

PMID:
23502769
8.

Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: a corollary study to EORTC trial 18952.

Bouwhuis MG, Suciu S, Kruit W, Salès F, Stoitchkov K, Patel P, Cocquyt V, Thomas J, Liénard D, Eggermont AM, Ghanem G; European Organisation for Research and Treatment of Cancer Melanoma Group.

Eur J Cancer. 2011 Feb;47(3):361-8. doi: 10.1016/j.ejca.2010.10.005. Epub 2010 Nov 17.

PMID:
21087856
9.

Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma.

Cuffel C, Rivals JP, Zaugg Y, Salvi S, Seelentag W, Speiser DE, Liénard D, Monnier P, Romero P, Bron L, Rimoldi D.

Int J Cancer. 2011 Jun 1;128(11):2625-34. doi: 10.1002/ijc.25607. Epub 2010 Oct 8.

10.

Vaccination of melanoma patients with Melan-A/Mart-1 peptide and Klebsiella outer membrane protein p40 as an adjuvant.

Lienard D, Avril MF, Le Gal FA, Baumgaertner P, Vermeulen W, Blom A, Geldhof C, Rimoldi D, Pagliusi S, Romero P, Dietrich PY, Corvaia N, Speiser DE.

J Immunother. 2009 Oct;32(8):875-83. doi: 10.1097/CJI.0b013e3181b56ad9.

PMID:
19752746
11.

Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients.

Vereecken P, Awada A, Suciu S, Castro G, Morandini R, Litynska A, Lienard D, Ezzedine K, Ghanem G, Heenen M.

Melanoma Res. 2009 Oct;19(5):316-20. doi: 10.1097/CMR.0b013e32832ec001.

PMID:
19581819
12.

Production of recombinant proteins in suspension-cultured plant cells.

Plasson C, Michel R, Lienard D, Saint-Jore-Dupas C, Sourrouille C, de March GG, Gomord V.

Methods Mol Biol. 2009;483:145-61. doi: 10.1007/978-1-59745-407-0_9.

PMID:
19183898
13.

Physcomitrella patens: a non-vascular plant for recombinant protein production.

Liénard D, Nogué F.

Methods Mol Biol. 2009;483:135-44. doi: 10.1007/978-1-59745-407-0_8.

PMID:
19183897
14.

From Neanderthal to nanobiotech: from plant potions to pharming with plant factories.

Sourrouille C, Marshall B, Liénard D, Faye L.

Methods Mol Biol. 2009;483:1-23. doi: 10.1007/978-1-59745-407-0_1. Review.

PMID:
19183890
15.

Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients.

Cherix S, Speiser M, Matter M, Raffoul W, Liénard D, Theumann N, Mouhsine E, Mirimanoff RO, Leyvraz S, Lejeune FJ, Leyvraz PF.

J Surg Oncol. 2008 Sep 1;98(3):148-55. doi: 10.1002/jso.21081.

PMID:
18668638
16.

A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites.

Kuemmerle A, Decosterd LA, Buclin T, Liénard D, Stupp R, Chassot PG, Mosimann F, Lejeune F.

Cancer Chemother Pharmacol. 2009 Jan;63(2):331-41. doi: 10.1007/s00280-008-0743-5. Epub 2008 Jun 28.

PMID:
18587581
17.

Water transport by aquaporins in the extant plant Physcomitrella patens.

Liénard D, Durambur G, Kiefer-Meyer MC, Nogué F, Menu-Bouaouiche L, Charlot F, Gomord V, Lassalles JP.

Plant Physiol. 2008 Mar;146(3):1207-18. doi: 10.1104/pp.107.111351. Epub 2008 Jan 9.

18.

Sentinel lymph node involvement and a high Breslow index are independent factors of risk for early relapse of melanoma.

Willi JP, Matter M, Buchegger F, Antonescu C, Guggisberg D, Cerottini JP, Krischer J, Braun R, Marie Kurt A, Roche B, Lemoine R, Rimoldi D, Lejeune FJ, Liénard D, Bischof Delaloye A.

Nuklearmedizin. 2007;46(6):244-51.

19.
20.

Pharming and transgenic plants.

Liénard D, Sourrouille C, Gomord V, Faye L.

Biotechnol Annu Rev. 2007;13:115-47. Review.

PMID:
17875476
21.

The role of interval nodes in sentinel lymph node mapping and dissection for melanoma patients.

Matter M, Nicod Lalonde M, Allaoua M, Boubaker A, Liénard D, Gugerli O, Cerottini JP, Bouzourene H, Bischof Delaloye A, Lejeune F.

J Nucl Med. 2007 Oct;48(10):1607-13. Epub 2007 Sep 14.

22.

Prognostic value of sentinel node biopsy in 327 prospective melanoma patients from a single institution.

Roulin D, Matter M, Bady P, Liénard D, Gugerli O, Boubaker A, Bron L, Lejeune FJ.

Eur J Surg Oncol. 2008 Jun;34(6):673-9. Epub 2007 Sep 6.

PMID:
17825518
23.

Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma.

Elliott B, Scolyer RA, Suciu S, Lebecque S, Rimoldi D, Gugerli O, Musat E, Sharma RN, Lienard D, Keilholz U, Testori A, Eggermont A, MacKie R, Robert C, Cook M, Thompson JF, Angevin E, Spatz A; European Organization for Research and Treatment of Cancer Melanoma Group.

Clin Cancer Res. 2007 Jul 1;13(13):3825-30.

24.

Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma.

Appay V, Voelter V, Rufer N, Reynard S, Jandus C, Gasparini D, Lienard D, Speiser DE, Schneider P, Cerottini JC, Romero P, Leyvraz S.

J Immunother. 2007 Feb-Mar;30(2):240-50.

PMID:
17471171
25.

Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.

Schmidt H, Suciu S, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, von der Maase H, Eggermont AM, Keilholz U; American Joint Committee on Cancer Stage IV Melanoma; EORTC 18951.

J Clin Oncol. 2007 Apr 20;25(12):1562-9.

PMID:
17443000
26.

IL-12 controls cytotoxicity of a novel subset of self-antigen-specific human CD28+ cytolytic T cells.

Barbey C, Baumgaertner P, Devevre E, Rubio-Godoy V, Derre L, Bricard G, Guillaume P, Luescher IF, Liénard D, Cerottini JC, Romero P, Rufer N, Speiser DE.

J Immunol. 2007 Mar 15;178(6):3566-74.

27.

Suspension-cultured BY-2 tobacco cells produce and mature immunologically active house dust mite allergens.

Lienard D, Tran Dinh O, van Oort E, Van Overtvelt L, Bonneau C, Wambre E, Bardor M, Cosette P, Didier-Laurent A, de Borne FD, Delon R, van Ree R, Moingeon P, Faye L, Gomord V.

Plant Biotechnol J. 2007 Jan;5(1):93-108.

29.

New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site.

Appay V, Jandus C, Voelter V, Reynard S, Coupland SE, Rimoldi D, Lienard D, Guillaume P, Krieg AM, Cerottini JC, Romero P, Leyvraz S, Rufer N, Speiser DE.

J Immunol. 2006 Aug 1;177(3):1670-8.

30.

A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination.

Speiser DE, Baumgaertner P, Barbey C, Rubio-Godoy V, Moulin A, Corthesy P, Devevre E, Dietrich PY, Rimoldi D, Liénard D, Cerottini JC, Romero P, Rufer N.

J Immunol. 2006 Jul 15;177(2):1338-48.

31.

Efficiency of recombinant human TNF in human cancer therapy.

Lejeune FJ, Liénard D, Matter M, Rüegg C.

Cancer Immun. 2006 Mar 22;6:6. Review.

32.

Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens.

Baumgaertner P, Rufer N, Devevre E, Derre L, Rimoldi D, Geldhof C, Voelter V, Liénard D, Romero P, Speiser DE.

Cancer Res. 2006 Feb 15;66(4):1912-6.

33.

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.

Eggermont AM, Suciu S, MacKie R, Ruka W, Testori A, Kruit W, Punt CJ, Delauney M, Sales F, Groenewegen G, Ruiter DJ, Jagiello I, Stoitchkov K, Keilholz U, Lienard D; EORTC Melanoma Group.

Lancet. 2005 Oct 1;366(9492):1189-96.

PMID:
16198768
34.

Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.

Keilholz U, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, Thomas J, Proebstle TM, Schmittel A, Schadendorf D, Velu T, Negrier S, Kleeberg U, Lehman F, Suciu S, Eggermont AM.

J Clin Oncol. 2005 Sep 20;23(27):6747-55.

PMID:
16170182
35.

Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.

van Baren N, Bonnet MC, Dréno B, Khammari A, Dorval T, Piperno-Neumann S, Liénard D, Speiser D, Marchand M, Brichard VG, Escudier B, Négrier S, Dietrich PY, Maraninchi D, Osanto S, Meyer RG, Ritter G, Moingeon P, Tartaglia J, van der Bruggen P, Coulie PG, Boon T.

J Clin Oncol. 2005 Dec 10;23(35):9008-21. Epub 2005 Aug 1.

PMID:
16061912
36.

[Cancer screening: when and how?].

Leupin N, Bauer J, Lüthi F, Liénard D, Vulliémoz D, Leyvraz S.

Rev Med Suisse. 2005 May 18;1(20):1328-30, 1333-4. Review. French.

PMID:
15991624
37.

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

Speiser DE, Liénard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, Krieg AM, Cerottini JC, Romero P.

J Clin Invest. 2005 Mar;115(3):739-46.

38.

Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA.

Liénard D, Rimoldi D, Marchand M, Dietrich PY, van Baren N, Geldhof C, Batard P, Guillaume P, Ayyoub M, Pittet MJ, Zippelius A, Fleischhauer K, Lejeune F, Cerottini JC, Romero P, Speiser DE.

Cancer Immun. 2004 May 19;4:4.

39.

Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance.

Zippelius A, Batard P, Rubio-Godoy V, Bioley G, Liénard D, Lejeune F, Rimoldi D, Guillaume P, Meidenbauer N, Mackensen A, Rufer N, Lubenow N, Speiser D, Cerottini JC, Romero P, Pittet MJ.

Cancer Res. 2004 Apr 15;64(8):2865-73.

40.

Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma.

Movassagh M, Spatz A, Davoust J, Lebecque S, Romero P, Pittet M, Rimoldi D, Liénard D, Gugerli O, Ferradini L, Robert C, Avril MF, Zitvogel L, Angevin E.

Cancer Res. 2004 Mar 15;64(6):2192-8.

41.

Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells.

Speiser DE, Pittet MJ, Rimoldi D, Guillaume P, Luescher IF, Liénard D, Lejeune F, Cerottini JC, Romero P.

Semin Cancer Biol. 2003 Dec;13(6):461-72. Review.

PMID:
15001165
42.

Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis.

Kleeberg UR, Suciu S, Bröcker EB, Ruiter DJ, Chartier C, Liénard D, Marsden J, Schadendorf D, Eggermont AM; EORTC Melanoma Group in cooperation with the German Cancer Society (DKG).

Eur J Cancer. 2004 Feb;40(3):390-402.

PMID:
14746858
43.

Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.

Valmori D, Dutoit V, Ayyoub M, Rimoldi D, Guillaume P, Liénard D, Lejeune F, Cerottini JC, Romero P, Speiser DE.

Cancer Immun. 2003 Oct 28;3:15.

44.

Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus.

Karanikas V, Lurquin C, Colau D, van Baren N, De Smet C, Lethé B, Connerotte T, Corbière V, Demoitié MA, Liénard D, Dréno B, Velu T, Boon T, Coulie PG.

J Immunol. 2003 Nov 1;171(9):4898-904.

45.

Lack of BRAF mutations in uveal melanoma.

Rimoldi D, Salvi S, Liénard D, Lejeune FJ, Speiser D, Zografos L, Cerottini JC.

Cancer Res. 2003 Sep 15;63(18):5712-5.

46.

Detection of micrometastases in sentinel lymph nodes from melanoma patients: direct comparison of multimarker molecular and immunopathological methods.

Rimoldi D, Lemoine R, Kurt AM, Salvi S, Berset M, Matter M, Roche B, Cerottini JP, Guggisberg D, Krischer J, Braun R, Willi JP, Antonescu C, Slosman D, Lejeune FJ, Liénard D; Groupe Mélanome Lémanique.

Melanoma Res. 2003 Oct;13(5):511-20.

PMID:
14512793
47.

Disease-driven T cell activation predicts immune responses to vaccination against melanoma.

Speiser DE, Rimoldi D, Batard P, Liénard D, Lejeune F, Cerottini JC, Romero P.

Cancer Immun. 2003 Sep 9;3:12.

48.

Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1.

Ayyoub M, Zippelius A, Pittet MJ, Rimoldi D, Valmori D, Cerottini JC, Romero P, Lejeune F, Liénard D, Speiser DE.

Clin Cancer Res. 2003 Feb;9(2):669-77.

49.

Isolated limb perfusion: distinct tourniquet and tumor necrosis factor effects on the early hemodynamic response.

Christoforidis D, Chassot PG, Mosimann F, Lienard D, Brunstein F, Bejko D, Lejeune FJ, Chiolero R.

Arch Surg. 2003 Jan;138(1):17-25.

PMID:
12511144
50.

Therapeutic cancer vaccines based on molecularly defined human tumor antigens.

Romero P, Pittet M, Dutoit V, Zippelius A, Liénard D, Lejeune F, Guillaume P, Rimoldi D, Valmori D, Speiser DE, Cerottini JC.

Vaccine. 2002 Dec 19;20 Suppl 4:A2-7.

PMID:
12477422

Supplemental Content

Loading ...
Support Center